KINIKSA target price at $27.81 +37.4%Kiniksa has activated a double bottom chart pattern that may lead the price to $27.81 that is +37.4% from current price.
Next report date
Report period
Q2 2024
EPS estimate
0.00USD
Revenue estimate
88.53 MUSD
0.12USD
14.08 MUSD
270.26 MUSD
38.19 M
About Kiniksa Pharmaceuticals, Ltd.
Sector
CEO
Sanj K. Patel
Headquarters
Lexington
Website
Employees (FY)
297
Founded
2015
ISIN
BMG5269C1010
FIGI
BBG00KT2KFX7
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.
KNSA Ascending Triangle and PDFUAHello,
Please pardon my charting. I find it is best to combine TA and some DD for the best trades lately. Definitely a solid level of resistance and higher lows in the weeks leading up.
Notes regarding the drug in question, Rilonacept, which addresses recurrent pericarditis.
"In RHAPSODY, the pr
Rising wedge rising wedge fda approval date is the 21st and has priority review i bought in and doubled my shares of dip today
KNSA PDUFA PlayLooking to see if PDUFA pushes this past upper resistance levels. Monthly huge inverse head and shoulder pattern. This one is set to move higher.
KNSA Harmonics: 270% Gain in One to Two YearsFundamental and Technical Update coming soon! (Check Below for entry harmonic pattern.)
Ride the MomentumAnnounced that six COVID-19 patients treated with mavrilimumab in Italy all responded to treatment, and 3 patients were discharged within 5 days.
A follow-on controlled study in Italy is planned. Shares closed the week up 43% to $17.91.
- BioPharmCatalyst
Breaking through the recent top will be a s
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of KNSA is 18.01 USD — it has increased by 0.84% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Kiniksa Pharmaceuticals, Ltd. stocks are traded under the ticker KNSA.
Kiniksa Pharmaceuticals, Ltd. is going to release the next earnings report on Jul 31, 2024. Keep track of upcoming events with our Earnings Calendar.
KNSA stock is 3.49% volatile and has beta coefficient of 0.95. Check out the list of the most volatile stocks — is Kiniksa Pharmaceuticals, Ltd. there?
KNSA earnings for the last quarter are 0.35 USD per share, whereas the estimation was −0.10 USD resulting in a 455.81% surprise. The estimated earnings for the next quarter are −0.08 USD per share. See more details about Kiniksa Pharmaceuticals, Ltd. earnings.
Kiniksa Pharmaceuticals, Ltd. revenue for the last quarter amounts to 83.40 M USD despite the estimated figure of 73.25 M USD. In the next quarter revenue is expected to reach 76.97 M USD.
Yes, you can track Kiniksa Pharmaceuticals, Ltd. financials in yearly and quarterly reports right on TradingView.
KNSA stock has risen by 6.00% compared to the previous week, the month change is a 10.89% fall, over the last year Kiniksa Pharmaceuticals, Ltd. has showed a 63.28% increase.
KNSA net income for the last quarter is −17.70 M USD, while the quarter before that showed 25.24 M USD of net income which accounts for −170.15% change. Track more Kiniksa Pharmaceuticals, Ltd. financial stats to get the full picture.
Today Kiniksa Pharmaceuticals, Ltd. has the market capitalization of 1.26 B, it has decreased by 2.09% over the last week.
No, KNSA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, KNSA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Kiniksa Pharmaceuticals, Ltd. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 297.00 employees. See our rating of the largest employees — is Kiniksa Pharmaceuticals, Ltd. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Kiniksa Pharmaceuticals, Ltd. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Kiniksa Pharmaceuticals, Ltd. stock shows the buy signal. See more of Kiniksa Pharmaceuticals, Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Kiniksa Pharmaceuticals, Ltd. future price: according to them, KNSA price has a max estimate of 32.00 USD and a min estimate of 26.00 USD. Read a more detailed Kiniksa Pharmaceuticals, Ltd. forecast: see what analysts think of Kiniksa Pharmaceuticals, Ltd. and suggest that you do with its stocks.